Evidence map›Paper›PMID 38848061›Full record

ArticleJAMA network open2024

Biomarkers of Neurobiologic Recovery in Adults With Sport-Related Concussion.

William T O'Brien, Gershon Spitz, Becca Xie, Brendan P Major, Steven Mutimer, Lauren P Giesler, Jesse Bain, Lauren J Evans, Beatriz Duarte Martins, Stefan Piantella and 20 more

Abstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

William T O'BrienDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Gershon SpitzDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Becca XieDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Brendan P MajorDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Steven MutimerDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Lauren P GieslerDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Jesse BainDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Lauren J EvansDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Beatriz Duarte MartinsDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Stefan PiantellaDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Afizu AlhassanDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Shelby BradyDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
David CappellariDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Vincenzo SommaDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Thomas McCollDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Georgia F SymonsDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Tenae GoreDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Matthew SunDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Timothy KuekDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Seamus HoranDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Michael BeiDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Jennie L PonsfordMonash-Epworth Rehabilitation Research Centre, School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia.
Catherine WillmottMonash-Epworth Rehabilitation Research Centre, School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia.
Jonathan ReyesMonash-Epworth Rehabilitation Research Centre, School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia.
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Biswadev MitraEmergency & Trauma Centre, The Alfred Hospital, Australia.
Terence J O'BrienDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Sandy R ShultzDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.
Stuart J McDonaldDepartment of Neuroscience, Monash University, Melbourne, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Sport-related concussion (SRC), a form of mild traumatic brain injury, is a prevalent occurrence in collision sports. There are no well-established approaches for tracking neurobiologic recovery after SRC. Objective: To examine the levels of serum glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) in Australian football athletes who experience SRC. Design, Setting, and Participants: A cohort study recruiting from April 10, 2021, to September 17, 2022, was conducted through the Victorian Amateur Football Association, Melbourne, Australia. Participants included adult Australian football players with or without SRC. Data analysis was performed from May 26, 2023, to March 27, 2024. Exposure: Sport-related concussion, defined as at least 1 observable sign and/or 2 or more symptoms. Main Outcomes and Measures: Primary outcomes were serum GFAP and NfL levels at 24 hours, and 1, 2, 4, 6, 8, 12, and 26 weeks. Secondary outcomes were symptoms, cognitive performance, and return to training times. Results: Eighty-one individuals with SRC (median age, 22.8 [IQR, 21.3-26.0] years; 89% male) and 56 control individuals (median age, 24.6 [IQR, 22.4-27.3] years; 96% male) completed a total of 945 of 1057 eligible testing sessions. Compared with control participants, those with SRC exhibited higher GFAP levels at 24 hours (mean difference [MD] in natural log, pg/mL, 0.66 [95% CI, 0.50-0.82]) and 4 weeks (MD, 0.17 [95% CI, 0.02-0.32]), and NfL from 1 to 12 weeks (1-week MD, 0.31 [95% CI, 0.12-0.51]; 2-week MD, 0.38 [95% CI, 0.19-0.58]; 4-week MD, 0.31 [95% CI, 0.12-0.51]; 6-week MD, 0.27 [95% CI, 0.07-0.47]; 8-week MD, 0.36 [95% CI, 0.15-0.56]; and 12-week MD, 0.25 [95% CI, 0.04-0.46]). Growth mixture modeling identified 2 GFAP subgroups: extreme prolonged (16%) and moderate transient (84%). For NfL, 3 subgroups were identified: extreme prolonged (7%), moderate prolonged (15%), and minimal or no change (78%). Individuals with SRC who reported loss of consciousness (LOC) (33% of SRC cases) had higher GFAP at 24 hours (MD, 1.01 [95% CI, 0.77-1.24]), 1 week (MD, 0.27 [95% CI, 0.06-0.49]), 2 weeks (MD, 0.21 [95% CI, 0.004-0.42]) and 4 weeks (MD, 0.34 [95% CI, 0.13-0.55]), and higher NfL from 1 week to 12 weeks (1-week MD, 0.73 [95% CI, 0.42-1.03]; 2-week MD, 0.91 [95% CI, 0.61-1.21]; 4-week MD, 0.90 [95% CI, 0.59-1.20]; 6-week MD, 0.81 [95% CI, 0.50-1.13]; 8-week MD, 0.73 [95% CI, 0.42-1.04]; and 12-week MD, 0.54 [95% CI, 0.22-0.85]) compared with SRC participants without LOC. Return to training times were longer in the GFAP extreme compared with moderate subgroup (incident rate ratio [IRR], 1.99 [95% CI, 1.69-2.34]; NfL extreme (IRR, 3.24 [95% CI, 2.63-3.97]) and moderate (IRR, 1.43 [95% CI, 1.18-1.72]) subgroups compared with the minimal subgroup, and for individuals with LOC compared with those without LOC (IRR, 1.65 [95% CI, 1.41-1.93]). Conclusions and Relevance: In this cohort study, a subset of SRC cases, particularly those with LOC, showed heightened and prolonged increases in GFAP and NfL levels, that persisted for at least 4 weeks. These findings suggest that serial biomarker measurement could identify such cases, guiding return to play decisions based on neurobiologic recovery. While further investigation is warranted, the association between prolonged biomarker elevations and LOC may support the use of more conservative return to play timelines for athletes with this clinical feature.

Indexed as

Athletic InjuriesBiomarkersBrain ConcussionGlial Fibrillary Acidic ProteinAdultAthletesAustraliaCohort StudiesFemaleFootballHumansMaleNeurofilament ProteinsRecovery of FunctionYoung AdultBiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament Proteins

Identifiers

PMID38848061
PMCPMC11161851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.